Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with β adrenergic antagonists</title>
<author><name sortKey="Nordmann, J" sort="Nordmann, J" uniqKey="Nordmann J" first="J." last="Nordmann">J. Nordmann</name>
</author>
<author><name sortKey="Soderstrom, M" sort="Soderstrom, M" uniqKey="Soderstrom M" first="M." last="Soderstrom">M. Soderstrom</name>
</author>
<author><name sortKey="Rouland, J" sort="Rouland, J" uniqKey="Rouland J" first="J." last="Rouland">J. Rouland</name>
</author>
<author><name sortKey="Malecaze, F" sort="Malecaze, F" uniqKey="Malecaze F" first="F." last="Malecaze">F. Malecaze</name>
</author>
<author><name sortKey="The, F" sort="The, F" uniqKey="The F" first="F" last="The">F. The</name>
</author>
<author><name sortKey="The, S" sort="The, S" uniqKey="The S" first="S" last="The">S. The</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">10655195</idno>
<idno type="pmc">1723381</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1723381</idno>
<idno type="RBID">PMC:1723381</idno>
<idno type="doi">10.1136/bjo.84.2.181</idno>
<date when="2000">2000</date>
<idno type="wicri:Area/Pmc/Corpus">000182</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with β adrenergic antagonists</title>
<author><name sortKey="Nordmann, J" sort="Nordmann, J" uniqKey="Nordmann J" first="J." last="Nordmann">J. Nordmann</name>
</author>
<author><name sortKey="Soderstrom, M" sort="Soderstrom, M" uniqKey="Soderstrom M" first="M." last="Soderstrom">M. Soderstrom</name>
</author>
<author><name sortKey="Rouland, J" sort="Rouland, J" uniqKey="Rouland J" first="J." last="Rouland">J. Rouland</name>
</author>
<author><name sortKey="Malecaze, F" sort="Malecaze, F" uniqKey="Malecaze F" first="F." last="Malecaze">F. Malecaze</name>
</author>
<author><name sortKey="The, F" sort="The, F" uniqKey="The F" first="F" last="The">F. The</name>
</author>
<author><name sortKey="The, S" sort="The, S" uniqKey="The S" first="S" last="The">S. The</name>
</author>
</analytic>
<series><title level="j">The British Journal of Ophthalmology</title>
<idno type="ISSN">0007-1161</idno>
<idno type="eISSN">1468-2079</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><italic>AIMS</italic>
—To compare the effect on intraocular pressure (IOP) of latanoprost monotherapy and timolol-pilocarpine in patients with glaucoma or ocular hypertension with inadequately controlled IOP on topical β adrenergic antagonists.
<italic>METHODS</italic>
—This was a multicentre, randomised, observer masked, 6 week study performed in France and Sweden. 23 centres enrolled 237<sup> </sup>
patients with glaucoma or ocular hypertension and an IOP of at least 22 mm Hg on treatment with topical β adrenergic antagonists, alone or in combination. After a 21 day run in period on timolol 0.5% twice daily, patients were randomised either to latanoprost 0.005% once daily or to a fixed combination of timolol-pilocarpine twice daily. Changes in mean diurnal IOP from the baseline to the 6 week visit were determined with an analysis of covariance.
<italic>RESULTS</italic>
—Mean diurnal IOP was statistically significantly decreased from baseline in both groups (p<0.001). Switching to latanoprost treatment reduced mean diurnal IOP by 5.4 (SEM 0.3) mm Hg (ANCOVA −22%) and switching to timolol-pilocarpine treatment reduced mean diurnal IOP by 4.9 (0.4) mm Hg (−20%). Blurred vision, decreased visual acuity, decreased twilight vision, and headache were statistically significantly more frequent in the timolol-pilocarpine group.
<italic>CONCLUSIONS</italic>
—Latanoprost monotherapy was at least as effective as fixed combination timolol-pilocarpine twice daily treatment in reducing mean diurnal IOP in patients not adequately controlled on topical β adrenergic antagonists. Latanoprost was better tolerated than timolol-pilocarpine regarding side effects. These results indicate that a switch to latanoprost monotherapy can be attempted before combination therapy is initiated.
</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Ophthalmol</journal-id>
<journal-title>The British Journal of Ophthalmology</journal-title>
<issn pub-type="ppub">0007-1161</issn>
<issn pub-type="epub">1468-2079</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">10655195</article-id>
<article-id pub-id-type="pmc">1723381</article-id>
<article-id pub-id-type="doi">10.1136/bjo.84.2.181</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Original articles - Clinical science</subject>
</subj-group>
</article-categories>
<title-group><article-title>Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with β adrenergic antagonists</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Nordmann</surname>
<given-names>J.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Soderstrom</surname>
<given-names>M.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Rouland</surname>
<given-names>J.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Malecaze</surname>
<given-names>F.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>the</surname>
<given-names>F</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>the</surname>
<given-names>S</given-names>
</name>
</contrib>
</contrib-group>
<aff>Department of Ophthalmology, Hôpital des Quinze-Vingts, Paris, France.</aff>
<pub-date pub-type="ppub"><month>2</month>
<year>2000</year>
</pub-date>
<volume>84</volume>
<issue>2</issue>
<fpage>181</fpage>
<lpage>185</lpage>
<self-uri xlink:role="pdf" xlink:type="simple" xlink:href="http://bjo.bmj.com/cgi/reprint/84/2/181.pdf"></self-uri>
<self-uri xlink:role="abstract" xlink:type="simple" xlink:href="http://bjo.bmj.com/cgi/content/abstract/84/2/181"></self-uri>
<self-uri xlink:role="fulltext" xlink:type="simple" xlink:href="http://bjo.bmj.com/cgi/content/full/84/2/181"></self-uri>
<abstract><p><italic>AIMS</italic>
—To compare the effect on intraocular pressure (IOP) of latanoprost monotherapy and timolol-pilocarpine in patients with glaucoma or ocular hypertension with inadequately controlled IOP on topical β adrenergic antagonists.
<italic>METHODS</italic>
—This was a multicentre, randomised, observer masked, 6 week study performed in France and Sweden. 23 centres enrolled 237<sup> </sup>
patients with glaucoma or ocular hypertension and an IOP of at least 22 mm Hg on treatment with topical β adrenergic antagonists, alone or in combination. After a 21 day run in period on timolol 0.5% twice daily, patients were randomised either to latanoprost 0.005% once daily or to a fixed combination of timolol-pilocarpine twice daily. Changes in mean diurnal IOP from the baseline to the 6 week visit were determined with an analysis of covariance.
<italic>RESULTS</italic>
—Mean diurnal IOP was statistically significantly decreased from baseline in both groups (p<0.001). Switching to latanoprost treatment reduced mean diurnal IOP by 5.4 (SEM 0.3) mm Hg (ANCOVA −22%) and switching to timolol-pilocarpine treatment reduced mean diurnal IOP by 4.9 (0.4) mm Hg (−20%). Blurred vision, decreased visual acuity, decreased twilight vision, and headache were statistically significantly more frequent in the timolol-pilocarpine group.
<italic>CONCLUSIONS</italic>
—Latanoprost monotherapy was at least as effective as fixed combination timolol-pilocarpine twice daily treatment in reducing mean diurnal IOP in patients not adequately controlled on topical β adrenergic antagonists. Latanoprost was better tolerated than timolol-pilocarpine regarding side effects. These results indicate that a switch to latanoprost monotherapy can be attempted before combination therapy is initiated.
</p>
</abstract>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000182 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000182 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/France |area= LeHavreV1 |flux= Pmc |étape= Corpus |type= RBID |clé= |texte= }}
This area was generated with Dilib version V0.6.25. |